Upload Avatar (500 x 500)
Su-Ling Liu
Biomedical Sciences
Fudan University
Shanghai
Language: English, Chinese
Breast Cancer
Stem Cells
Heterogeneity
Regulation
Drug Resistance
Tumor Microenvironment
Immune Regulation
Therapeutic Strategies
Drug Development
Cancer Research
Areas of Focus
- Heterogeneity and regulation of breast cancer stem cells and drug resistance
- Origin of breast cancer stem cells
- Interaction between tumor microenvironment and cancer stem cells
- Immune regulation of cancer stem cells
- New therapeutic strategies targeting cancer stem cells and drug development
Work Experience
- 2016.12-Present - Fudan University - Professor, Biomedical Research Institute/Affiliated Cancer Hospital
- 2012.11-2016.11 - University of Science and Technology of China - Professor, School of Life Sciences
- 2010.10-2012.10 - University of Michigan - Research Assistant Professor
- 2006.10-2010.09 - University of Michigan - Assistant Researcher
- 2003.12-2006.09 - University of Michigan - Postdoctoral Researcher
Academic Background & Achievements
- 1997-2003 Ph.D.: Ohio State University, Department of Biology
- 1992-1997 Bachelor's: University of Science and Technology of China, Department of Biology
- 2021 Shanghai Leading Talent, Shanghai Municipal Party Committee and Shanghai Human Resources and Social Security Bureau
- 2020 Young and Middle-aged Leading Talent in Scientific and Technological Innovation, Ministry of Science and Technology
- 2020 Academic Leader of Shanghai Science and Technology Innovation Action Plan
- 2020 Fudan University 'Excellence 2025': Outstanding Talent
- 2019 Shanghai Medical Leading Talent, Shanghai Municipal Health Commission
- 2014 National Excellent Young Scientist Fund, National Natural Science Foundation of China
- 2012 Youth Project of Overseas High-level Talent Introduction Program, Central Organization Department
Publications
- Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization, Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., Wang, D., Li, F., Liu, Y., He, X., Duan, S., Zhang, L., Liu, T.*, Liu, S.*, 2022
- Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity, Zhang, R.#, Tu, J.#, Liu, S.*, 2022
- TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer, Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., Zhang, R., Lei, Q., Shao, Z-M., Bian, X.*, Hu, R.*, Zhang, L.*, Liu, S.*, 2021
- ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression, Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., Lv, J., Yu, Z., Lei, Q., Shao, Z.*, Zhang, X.*, Zhang, L.*, Liu, S.*, 2021
- Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression, Jiang, G.#, Tu, J.#, Zhou, L.#, Dong, M., Fan, J., Chang, Z., Zhang, L., Bian, X., Liu, S.*, 2021
- Cancer Stem Cells and Neovascularization, Li, F. #, Xu, J. #, Liu, S.*, 2021
- Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity, Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.*,Pan, Y.*, Jiang, W.*, Zhou R.*, 2020
- UCP1 regulates ALDH-positive breast cancer stem cells through releasing the suppression of Snail on FBP1, Zhang, F. #, Liu, B., Deng, Q., Sheng, D., Xu, J., He, X., Zhang, L.*, Liu, S.*, 2020
- Mechanistic insights of adipocyte metabolism in regulating breast cancer progression, Zhang, F. #, Liu, S.*, 2020
- Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu, S.*, 2020
- IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability, Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S.*, 2020
- NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer, Zhou， L. #, Wang, D. #, Sheng, D. #, Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N.*, Liu, S.*, Zhang, L.*, 2020
- Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling, Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S.*, Sun, L.*, 2019
- Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function, Jiang, G.#, Wang, X.#, Sheng, D., Zhou, L., Liu, Y., Xu, C., Liu, S.* and Zhang, J.*, 2019
- The endogenous retrovirus-derived long noncodingRNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation, Jin, X. #, Xu, X-E. # *, Jiang, Y-Z. #, Liu, Y-R., Sun, W., Guo, Y-J., Ren, Y-X., Zuo, W-J., Hu, X., Huang, S-L., Shen, H-J., Lan, F., He, Y-F., Hu, G-H., Di, G-H., He, X-H., Li, D-Q., Liu, S.*, Yu, K-D.*,, Shao, Z-M.*, 2019
- Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells, Cui, B., Luo, Y., Tian, P., Peng, F., Lu, J., Yang, Y., Su, Q., Liu, B., Yu, J., Luo, X., Yin, L., Cheng, W., An, F., He, B., Liang, D., Wu, S., Chu, P., Song, L., Liu, X., Luo, H., Xu, J., Pan, Y., Wang, Y., Li, D., Huang, P., Yang, Q., Zhang, L., Zhou, B.P., Liu, S., Xu, G.,Lam, E.W.-F., Kelley, K.W. and Liu, Q.*, 2019
- Targeting the BRD4/FOXO3a/CDK6 axis Sensitizes AKT Inhibition in Luminal Breast Cancer, Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng J., Stewart, R., Wang, C., Lin, P., Ghaffari, S., Evers, B.M., Liu, S.*, Zhou, M-M.*, Zhou, B.*, and Shi, J.*, 2018
- miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis, Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. *, Guan, J-L.*, and Liu, S.*, 2018
Awards
- 2020 WuXi AppTec Life Chemistry Research Award
- 2018 China Young Scientist Award in Oncology, Chinese Anti-Cancer Association
- 2014 Sino-American Anti-Cancer Association - National Cancer Foundation Academic Award
- 2010 Susan G. Komen Scholar in Training Award, American Cancer Society
- 2006 Merck Scholar in Training Award, American Cancer Society
